Atlas Crest Investment Corp. II (ACII)
Company Info
- ISINUS0492871050
- CUSIP49287105
- SectorFinancial Services
- IndustryShell Companies
Trading Data
- Previous Close$9.78
- Year Range$9.64 - $9.84
- EMA (50)$9.79
- EMA (200)$9.77
- Average Volume$97.67K
- Market Capitalization$421.55M
ACIIShare Price Chart
Click Calculate to get results
ACIIPerformance
The chart shows the growth of $10,000 invested in Atlas Crest Investment Corp. II on Mar 30, 2021 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $9,780 for a total return of roughly -2.20%. All prices are adjusted for splits and dividends.
ACIIReturns in periods
Period | Return | Benchmark |
---|---|---|
1M | -0.51% | -12.57% |
YTD | 0.51% | -18.14% |
6M | 0.20% | -17.07% |
1Y | 0.41% | -5.19% |
5Y | -1.92% | -1.52% |
10Y | -1.92% | -1.52% |
ACIIMonthly Returns Heatmap
Click Calculate to get results
ACIIDividend History
Atlas Crest Investment Corp. II doesn't pay dividends
ACIIDrawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
ACIIWorst Drawdowns
The table below shows the maximum drawdowns of the Atlas Crest Investment Corp. II. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.
The maximum drawdown since January 2010 for the Atlas Crest Investment Corp. II is 5.02%, recorded on Aug 27, 2021. The portfolio has not recovered from it yet.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-5.02% | Apr 6, 2021 | 101 | Aug 27, 2021 | — | — | — |
-3.4% | Mar 30, 2021 | 1 | Mar 30, 2021 | 3 | Apr 5, 2021 | 4 |
ACIIVolatility Chart
Current Atlas Crest Investment Corp. II volatility is 1.34%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.
Portfolios with Atlas Crest Investment Corp. II
Loading data...